This innovative technology, detailed in a study published on April 29, 2026, in the journal Nature, builds upon the foundation of prime editing—a precise gene-editing technique combining CRISPR-Cas9 and reverse transcriptase capabilities. The team of researchers, led collaboratively by Bin Liu of The Ohio State University College of Medicine and colleagues from the University of Massachusetts Chan Medical School, devised a method incorporating overlapping DNA flaps that seamlessly integrate donor DNA into the genome without causing the harmful double-strand breaks traditionally associated with large DNA insertions.

Prime assembly deftly circumvents the cytotoxic pitfalls commonly attributed to double-strand breaks in DNA, which can lead to cell death and hinder therapeutic efficacy. By leveraging programmable single-stranded DNA “flaps” generated via twin prime editing strategies, the system fosters a scenario where donor DNA with up to an astonishing 11,000 base pairs can be accurately inserted, representing a quantum leap over the previous limit of approximately 800 base pairs in gene editing. This capacity to transplant vast genetic sequences enables the correction of multiple heterogeneous mutations within a single therapeutic intervention, a feat previously considered unattainable due to regulatory and technical constraints.

The significance of this capability cannot be overstated. Many debilitating genetic diseases are caused by a constellation of mutations scattered throughout a gene or its regulatory regions. Traditional gene therapy approaches would require addressing these mutations individually, complicating development pipelines and requiring multiple approvals. Prime assembly simplifies this by replacing substantial genetic regions wholesale, akin to excising entire paragraphs or chapters from a genome “book” and replacing them with fresh, precise sequences that restore functionality.

Mechanistically, the process involves preparing the donor DNA in the laboratory, which serves as the “healthy” genetic template for insertion. The twin prime editing system creates complementary overlapping flaps on the target DNA locus. These flaps hybridize with ends of the donor DNA, enabling its integration into the genome without the need for error-prone DNA repair pathways like homology-directed repair, which is only efficient in dividing cells. This innovation notably broadens therapeutic applicability to non-dividing cells such as neurons and cardiomyocytes, cell types previously elusive targets for gene therapy.

The team’s in vitro assays in mammalian cells demonstrated not only the impressive efficiency of prime assembly but also its potential safety advantages, as the technique induces only a single-strand DNA break. Such breaks are less detrimental and less likely to trigger apoptosis or other adverse cellular responses compared to double-strand breaks. This attribute positions prime assembly as a powerful candidate for in vivo therapeutic applications where maintaining cellular integrity is paramount.

Further advancing translational potential, the researchers emphasized ongoing work to optimize delivery systems for both the donor DNA and gene editor components. Based on current gene therapy modalities, lipid nanoparticles or adeno-associated viruses (AAVs) are considered the leading vectors to transport these genetic payloads into patients’ cells effectively and safely. The versatility of prime assembly’s design promises compatibility with these delivery vehicles, setting the stage for imminent preclinical and clinical explorations.

Prime assembly inherits its name in homage to Gibson assembly cloning, a widely used molecular biology technique that joins multiple DNA fragments in vitro. Whereas Gibson assembly has revolutionized DNA construction in test tubes, prime assembly translates a similar conceptual framework into a cellular context, effecting large and precise genomic insertions directly inside living cells.

Looking ahead, the research team, including collaborators from Ohio State’s Gene Therapy Institute and experts like ophthalmologist Tom Mendel, plans to rigorously evaluate the efficacy, specificity, and safety of prime assembly in animal models. Such studies will critically inform its readiness for clinical application, potentially transforming treatment paradigms for a host of genetic disorders that have long eluded cure due to their complexity.

Underpinning this scientific leap are extensive collaborative efforts supported by prominent institutions such as the National Institutes of Health, the Leducq Foundation Transatlantic Network of Excellence Program, and the Cystic Fibrosis Foundation. These partnerships reflect the interdisciplinary and high-stakes nature of gene therapy research that melds cutting-edge molecular biology with patient-centered translational goals.

In sum, prime assembly emerges as a beacon of hope in the gene therapy field, promising to unlock large-scale genomic insertions hitherto thought impossible without compromising cell viability. The capacity to insert entire healthy genes tailored to a patient’s unique mutation spectrum could revolutionize treatment options, driving precision medicine deeper into the realm of curative care for heretofore intractable genetic diseases.

The long-term impact of prime assembly technology extends beyond therapeutic applications. It also offers a versatile platform for fundamental research, allowing scientists to study gene function and genomic architecture with unparalleled precision by introducing large, customizable DNA sequences into the genome. This may accelerate discovery across genetics, developmental biology, and regenerative medicine.

As prime assembly continues to mature through successive iterations of experimental validation, its transformative potential will likely catalyze new biotech innovations, spawning a generation of gene therapies that transcend the limitations of existing editing approaches. The future where complex genetic diseases can be robustly treated or cured through large-scale genomic replacement now feels within reach, marking a watershed moment in the annals of biomedical science.

— Written by Emily Caldwell, Emily.Caldwell@osu.edu

Subject of Research: Gene editing technology enabling large genomic insertions via prime assembly

Article Title: Prime assembly with linear DNA donors enables large genomic insertions

News Publication Date: 29-Apr-2026

Web References: https://www.nature.com/articles/s41586-026-10460-4

References: Liu B. et al., “Prime assembly with linear DNA donors enables large genomic insertions,” Nature, April 29, 2026.

Image Credits: Not provided

Keywords

Gene therapy, Prime editing, Large DNA insertion, Genome editing, Twin prime editing, Non-dividing cells, Single-strand break, Homology-directed repair, Lipid nanoparticle delivery, Adeno-associated virus, Genetic disease, Precision medicine

Frameshift mutations occur when insertions or deletions in the DNA alter the gene’s reading frame, resulting in aberrant or truncated proteins that often fail to perform normal cellular functions. The difficulty in targeting these anomalies arises primarily because current genome editing approaches typically rely on homology-directed repair mechanisms that require external templates and suffer from low efficiency, especially in non-dividing cells. TIGER overcomes these limitations by harnessing the power of precision guide RNA (gRNA) and the Cas9 nuclease, without the need for a DNA template to restore the correct reading frame. This template-free mechanism dramatically expands the scope of patients who could benefit from corrective therapy.

Central to TIGER’s success is a meticulous analysis of the nucleotide-level factors influencing editing outcomes. By systematically examining the patterns of insertions and deletions generated by CRISPR-Cas9 cuts, the research team deciphered reproducible sequence features that predict whether the edited product would be in-frame—meaning the reading frame is preserved or restored. Leveraging these insights, they developed a sophisticated scoring system to select the most promising gRNA sequences. This strategy consolidates editing efficiency with therapeutic potential, ensuring that a majority of indels (insertions or deletions) lead to functional protein restoration rather than dysfunctional gene products.

The results speak volumes about the technology’s potential. For deletion-based frameshift mutations, approximately 75% of edits resulted in in-frame sequences sufficient to restore normal gene expression and, crucially, phenotypic correction. Meanwhile, insertion mutations showed a similarly impressive trend, with about 50% achieving therapeutically relevant in-frame products. Furthermore, a striking proportion of these edits—38% of deletions and 65% of insertions—fully reinstated the wild-type sequence, effectively curing the genetic defect at the molecular level.

Expanding on TIGER’s versatility, the researchers successfully retrained an existing machine learning tool, inDelphi, to enhance its predictive power for therapeutic gRNAs targeting single-nucleotide frameshifts across various species. This retraining accounted for the idiosyncratic DNA repair outcomes and introduced a genome-wide applicability dimension crucial for translating TIGER into clinical settings. In doing so, the platform embraces both evolutionary conservation and species-specific genetic contexts, thereby facilitating personalized and cross-species gene therapy designs.

One of the most compelling demonstrations of TIGER’s therapeutic promise comes from a mouse model designed to mimic human deafness caused by frameshift mutations. Using dual adeno-associated virus (AAV) vectors, the researchers delivered SpCas9 and the optimized gRNA directly into the affected inner ear tissues. The treatment resulted in a remarkable restoration of hearing thresholds, returning them to wild-type levels. This outcome was not only a functional proof of concept but also underscored TIGER’s ability to produce targeted edits with about 90% of in-frame modifications perfectly restoring the wild-type sequence.

This in vivo success is particularly significant because it showcases TIGER’s precision in complex, post-mitotic tissues—cell types typically resistant to traditional genome editing techniques. Hearing restoration assays and detailed molecular analyses confirmed that the edited cellular populations maintained normal physiological function, thereby validating the approach’s safety and effectiveness. This landmark achievement suggests that TIGER could become the cornerstone for treating a variety of inherited frameshift disorders affecting diverse organ systems.

The implications of TIGER are profound. By circumventing the need for exogenous repair templates and leveraging endogenous cellular machinery through carefully selected gRNAs, the platform reduces off-target effects and enhances editing precision. This minimalist intervention minimizes immune responses and maximizes the functional correction of mutated genes, an especially critical consideration in clinical settings. Moreover, the versatility across different mutation types and species enhances TIGER’s potential as a universal genome editing solution.

Beyond hearing loss, the team foresees TIGER’s application extending to a myriad of inherited diseases where frameshift mutations drive pathology. These include various muscular dystrophies, cystic fibrosis variants, retinal degenerations, and metabolic disorders. The ability to non-invasively and efficiently restore gene function at the nucleotide level could redefine therapeutic paradigms, moving from symptom management to curative interventions.

From a technological perspective, TIGER’s development underscores the increasing role of computational biology in advancing genome editing. The integration of machine learning algorithms like the retrained inDelphi enables precise forecasting of editing outcomes, reducing experimental trial-and-error and streamlining translational research. This synergy between computational prediction and molecular engineering represents a new frontier in customizable gene therapies tailored to the unique genetic landscapes of patients.

The study also addresses concerns about the longevity and stability of genome edits. Longitudinal monitoring in the mouse deafness model revealed durable phenotypic restoration without detectable off-target mutagenesis or adverse immune responses. These findings enhance confidence in TIGER’s clinical viability and open avenues for longitudinal gene correction strategies, which could substantially improve patient outcomes over standard treatments.

Furthermore, TIGER’s reliance on dual AAV delivery systems capitalizes on their established efficacy and safety profiles in gene therapy. The ability to package and deliver gene editing components in tandem ensures synchronous action, critical for maximizing editing efficiency. This delivery strategy aligns well with current clinical gene therapy pipelines, facilitating a smoother path toward regulatory approval and clinical translation.

Looking ahead, the researchers are actively exploring the scalability of TIGER to human clinical trials. The robust framework for predicting and validating therapeutic gRNAs, combined with the demonstrated efficacy in animal models, positions TIGER as a frontrunner for correcting monogenic diseases previously deemed intractable. Collaborative efforts with biotech firms and medical institutions aim to accelerate this transition, with a focus on optimizing delivery methods, ensuring patient safety, and extending applicability to a broader spectrum of genetic disorders.

In summary, TIGER represents a watershed moment in genome editing and therapeutic restoration of frameshift mutations. By pioneering a template-independent, highly predictive, and efficient strategy, the platform opens transformative possibilities for the millions affected by inherited genetic diseases. Continuous advances in bioengineering, computational modeling, and in vivo validation promise to catapult TIGER from bench to bedside, heralding a new era of precision medicine driven by gene editing technologies.

Subject of Research: Template-Independent Genome Editing for Restoration (TIGER) targeting frameshift mutations in inherited diseases.

Article Title: Template-independent genome editing and restoration for correcting frameshift disorders.

Article References:
Qiu, S., Liu, L., Xiang, B. et al. Template-independent genome editing and restoration for correcting frameshift disorders. Nat. Biomed. Eng (2026). https://doi.org/10.1038/s41551-026-01635-5

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41551-026-01635-5